Abstract

Case Report

Maculopapular delayed exanthema due to ranitidine

Pilar Hernández Alfonso*, Idoia González Mahave, Irene Vidal Oribe, Mª Dolores del Pozo Gil, Mónica Venturini Díaz and Teófilo Lobera Labairu

Published: 23 December, 2020 | Volume 4 - Issue 1 | Pages: 014-016

Ranitidine is a widely used drug in Europe and its intake is usually well tolerated. Hypersensitivity reactions due to ranitidine are uncommon. The immediate mild reactions type are the most prevalent. In some special cases a delayed type reaction such as contact dermatitis or severe reactions with systemic involvement have been reported.

In the present paper, a case report of a 78-year old patient who experienced a maculopapular eruption after 7 days of oral treatment with ranitidine is described. Patch tests were performed twice with ranitidine with positive results confirming the diagnosis. In order to discard a double sensitization and a possible cross-reactivity phenomenon, patch test was performed once with famotidine, with a negative result. This is the first maculopapular exanthema reported as type IV hypersensitivity reaction to ranitidine confirmed by patch testing.

Moreover, there are only two reported cases showing a double sensitization to ranitidine and to other H2-receptor antagonists by patch testing after a delayed reaction due to ranitidine, the other being H2-receptor antagonists involving cimetidine and nizatidine, not famotidine.

Read Full Article HTML DOI: 10.29328/journal.adr.1001012 Cite this Article Read Full Article PDF

References

  1. Grant SM, Langtry HD, Brogden RN. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1989; 37: 801-870. PubMed: https://pubmed.ncbi.nlm.nih.gov/2667937/
  2. Revisión de los medicamentos que contienen ranitidina por la presencia de nitrosaminas [Internet]. Asociación Española de Mediacamentos y Productos Sanitarios. 2020. PubMed: https://www.aemps.gob.es/
  3. Mahase E. Ranitidine: patients taking certain batches should “immediately discontinue use,” says FDA. BMJ. 2019; l7053.
  4. Foti C, Cassano N, Panebianco R, Calogiuri G, Vena G. Hypersensitivity reaction to ranitidine: Description of a case and review of the literature. Immunopharmacol Immunotoxicol. 2009; 31: 414-416. PubMed: https://pubmed.ncbi.nlm.nih.gov/19694603/
  5. Okamoto O, Fujiwara S. Drug eruption caused by ranitidine hydrochloride (Zantac) which showed a strong reaction in a drug-induced lymphocyte stimulation test. J Dermatol. 2007; 34: 74-79. PubMed: https://pubmed.ncbi.nlm.nih.gov/17204107/
  6. Vérez A, Motreno JC. Second case of ranitidine related toxic epidermal necrolysis in a patient with idiopathic Thrombocytopenic purpura J Am Acad Dermatol. 2000; 42: 305. PubMed: https://pubmed.ncbi.nlm.nih.gov/10642697/
  7. Watts T, Haque R. DRESS Syndrome Induced by Ranitidine. The Journal of Allergy and Clinical Immunology: In Practice. 2018; 6: 1030-1031. PubMed: https://pubmed.ncbi.nlm.nih.gov/29102410/
  8. Palacios-Zabalza I, Camino-Rodríguez E, Aguirre C. Síndrome de Kounis inducido por ranitidina. Medicina Clínica. 2018; 151: e51-e53.
  9. Blanes Martínez M, Silvestre Salvador JF, Vergara Aguilera G, Betlloch Mas I, Pascual Ramirez JC. Acute generalized exanthematous pustulosis induced by ranitidine hydrochloride. Contact Dermatitis. 2003; 49-47. PubMed: https://pubmed.ncbi.nlm.nih.gov/14641127/
  10. Ryan PJ, Rycroft RJ, Aston IR. Allergic contact dermatitis from occupational exposure to ranitidine hydrocloride. Contact Dermatitis. 2003; 48: 67-68. PubMed: https://pubmed.ncbi.nlm.nih.gov/12694207/
  11. Herrera-Mozo I, Sanz-Gallen P, Martí-Amengual G. Occupational contact allergy to omeprazole and ranitidine. Medycyna Pracy. 2017; 68: 433-435. PubMed: https://pubmed.ncbi.nlm.nih.gov/28512370/
  12. Song W, Kim M, Lee S, Kwon Y, Kim S, et al. Two Cases of H2-Receptor Antagonist Hypersensitivity and Cross-Reactivity. Allergy, Asthma and Immunology Research. 2011; 3: 128-131. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062792/
  13. Morisset M, Moneret-Vautrin DA, Loppinet V, Grandidier S. Cross-allergy to ranitidine and nizatidine. Allergy. 2000; 55: 682-683. PubMed: https://pubmed.ncbi.nlm.nih.gov/10921476/
  14. Bocșan IC, Sabin O, Matei D, Muntean A, Buzoianu AD. How often we diagnose allergy to ranitidine? Eur Rev Med Pharmacol Sci. 2020; 24: 10812-10818. PubMed: https://pubmed.ncbi.nlm.nih.gov/33155242/
  15. Dwivedi S, Chopra D, Arora P, Khan S. Anaphylaxis following intravenous ranitidine: A rare adverse reaction of a common drug. Indian J Pharmacol. 2014; 46: 234-236. PubMed: https://pubmed.ncbi.nlm.nih.gov/24741203/
  16. Mori F, Barni S, Pecorari L, Sarti L, Pucci N, et al. Anaphylaxis to Intravenous Ranitidine in a Child. Pharmacology. 2015; 95: 240-242. PubMed: https://pubmed.ncbi.nlm.nih.gov/25967233/
  17. Yilmaz I, Turk M. Ranitidine-Induced Anaphylaxis in a Patient with Acute COPD Exacerbation. Turk Thorac J. 2017; 18: 94-95. PubMed: https://pubmed.ncbi.nlm.nih.gov/29404169/
  18. Bossi A, Romeo G, Pezzoli A. Side-effects, structure, and H2-receptor antagonists. Lancet. 1992; 339: 1366.PubMed: https://pubmed.ncbi.nlm.nih.gov/1350041/

Figures:

Figure 1

Figure 1

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?